NCT05525208 - Booster Study of COVID-19 Protein Subunit Recombinant Vaccine | Biotech Hunter

Enrollment

696

Participants

Timeline

Start Date

September 1, 2022

Primary Completion Date

July 2, 2023

Study Completion Date

August 4, 2023

Conditions

COVID-19

Interventions

BIOLOGICAL

SARS-CoV-2 subunit protein recombinant vaccine

SARS-CoV-2 RBD subunit recombinant protein, manufactured by PT. Bio Farma

BIOLOGICAL

Active Comparator

The Pfizer-BioNTech® COVID-19 vaccine or BNT162b2, is an mRNA vaccine encoding a P2 mutant spike protein (PS 2) and formulated as an RNA-lipid nanoparticle of nucleoside-modified mRNA (modRNA).

Trial Locations (2)

Unknown

Faculty of Medicine Universitas Udayana, Denpasar

Faculty of Medicine Universitas Padjadjaran, Bandung